Drug intelligence / Profile preview

BCMA-GPRC5D CAR-T cells (Donghua Zhang)

Development stage
Unknown
Lead developer
Donghua Zhang
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration
Intravenous
01

Overview

BCMA-GPRC5D CAR-T cells is an investigational dual-targeting chimeric antigen receptor (CAR) T-cell therapy developed by Donghua Zhang at Tongji Hospital. This cell therapy simultaneously targets two antigens highly expressed on malignant plasma cells: B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D). By utilizing a dual-targeting approach, the therapy is designed to enhance anti-tumor activity and mitigate the risk of disease relapse caused by antigen escape, a common limitation of single-target CAR-T therapies. It is currently being evaluated in clinical trials for patients with relapsed or refractory multiple myeloma who have undergone at least three prior lines of treatment.

Other names
BCMA-GPRC5D CAR-T cellsBCMA-GPRC-5D CAR-T cellsBCMA-GPRC 5D CAR-T cellsBCMA/GPRC5D dual-targeting CAR-T cellsBCMA-GPRC5D CAR-TBCMA-GPRC-5D CAR-TBCMA-GPRC 5D CAR-T
02

Targets

BCMA (B-cell maturation antigen)GPRC5D

Beyond the preview

Go deeper on BCMA-GPRC5D CAR-T cells (Donghua Zhang).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCMA-GPRC5D CAR-T cells (Donghua Zhang).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call